MarketCap
Facebook
X
TelegramAntares Pharma, Inc. Balance Sheet 2011-2026 | ATRS
Annual Balance Sheet Antares Pharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-12.2 M | 23.9 M | -2.77 M | -1.7 M | -27.7 M | -32.9 M | -34 M | -39.1 M | -52.1 M | -19.4 M |
Long Term Debt |
24.7 M | 40.4 M | 22.1 M | 24.9 M | - | - | - | - | - | - |
Total Non Current Liabilities |
30.2 M | 45.8 M | 22.1 M | 25.1 M | 1.2 M | 700 K | 3.35 M | 1.86 M | 1.04 M | 810 K |
Total Current Liabilities |
63.2 M | 32.4 M | 27.2 M | 15.7 M | 19.9 M | 16.8 M | 24.2 M | 16.4 M | 7.94 M | 10 M |
Total Liabilities |
93.4 M | 78.3 M | 49.3 M | 40.8 M | 21.1 M | 17.5 M | 27.6 M | 18.2 M | 8.98 M | 10.8 M |
Deferred Revenue |
3.94 M | 1.74 M | 1.02 M | 2.79 M | 6.15 M | 5.14 M | 8.52 M | 4.53 M | 2.16 M | 5.64 M |
Retained Earnings |
-223 M | -279 M | -277 M | -270 M | -253 M | -229 M | -208 M | -173 M | -153 M | -141 M |
Total Assets |
213 M | 133 M | 88.3 M | 74.3 M | 66.3 M | 84.6 M | 68.8 M | 88.9 M | 95.5 M | 42 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Antares Pharma, Inc., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
$ 29.85 | 1.05 % | $ 1.43 B |  USA |
 |
AngioDynamics
ANGO
|
$ 10.6 | -1.03 % | $ 433 M | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.47 | -4.15 % | $ 19.9 M | USA |
 |
Alcon
ALC
|
$ 77.32 | -1.5 % | $ 40.4 B |  Schweiz |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
ICU Medical
ICUI
|
$ 125.85 | -2.28 % | $ 3.1 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.31 | -0.85 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 113.0 | -1.46 % | $ 3.62 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 472.16 | -1.48 % | $ 169 B | USA |
 |
The Cooper Companies
COO
|
$ 69.92 | -2.24 % | $ 13.9 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 97.02 | -0.79 % | $ 4.7 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 159.36 | -0.17 % | $ 45.8 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 59.92 | 0.72 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
$ 6.14 | -3.0 % | $ 33.9 K | USA |
 |
Masimo Corporation
MASI
|
$ 175.49 | -0.01 % | $ 9.35 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 11.56 | -2.12 % | $ 28 M | USA |
 |
Repro Med Systems
KRMD
|
$ 4.28 | -0.7 % | $ 198 M | USA |
 |
Baxter International
BAX
|
$ 17.4 | -3.36 % | $ 8.93 B | USA |
 |
BioLife Solutions
BLFS
|
$ 18.36 | 1.16 % | $ 846 M | USA |
 |
Nephros
NEPH
|
$ 3.5 | -7.89 % | $ 36.4 M | USA |
 |
ResMed
RMD
|
$ 230.84 | -0.68 % | $ 33.7 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.71 | 2.62 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 69.95 | 2.61 % | $ 4.14 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 24.61 | -3.26 % | $ 4.13 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.84 | 2.45 % | $ 934 M | USA |
 |
Stereotaxis
STXS
|
$ 1.89 | 0.27 % | $ 172 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 107.32 | -0.87 % | $ 4.79 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.97 | -3.88 % | $ 218 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 108.06 | 1.43 % | $ 2.45 B | USA |
 |
Utah Medical Products
UTMD
|
$ 63.28 | 1.02 % | $ 230 M | USA |
 |
Pro-Dex
PDEX
|
$ 48.46 | 3.5 % | $ 159 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.69 | -1.47 % | $ 27.4 M |  Israel |
 |
West Pharmaceutical Services
WST
|
$ 235.46 | 1.89 % | $ 17 B | USA |
 |
Repligen Corporation
RGEN
|
$ 114.2 | 0.39 % | $ 6.36 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.54 | -2.2 % | $ 2.3 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 21.57 | 1.27 % | $ 1.45 B | USA |
 |
STERIS plc
STE
|
$ 214.57 | 1.05 % | $ 21.2 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.28 | -3.75 % | $ 22.3 M | USA |